Crexont (Carbidopa/Levodopa) Patent Expiration, LOE Window & CMS Spending

Crexont (Carbidopa/Levodopa) by Amneal Pharmaceuticals: FDA Orange Book LOE 2041-12-21, 18 AB generics, $2.6M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAmneal Pharmaceuticals
FDA Application & PathwayN217186 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2041-12-21
Orange Book Patents (*PED Extensions)30 patents (0 *PED)
Active AB-Rated Generic Competitors18
2024 CMS Total Public Spend$2.6M
2024 Medicare Part D Spend$2.5M
2024 Medicaid Spend$60K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel